Fig. 2From: Proof of principle for bevacizumab activity in desmoid-type fibromatosisT2-weighted MRI of the right shoulder after second tumor resection and prior to bevacizumab treatment (a), as well as 6 weeks (b), 4 months (c) and 14 months (d) after treatment initiation, showing a continuous tumor shrinkage over time (white arrows)Back to article page